Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-11-04
1993-02-09
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514274, 544311, A61K 31505, C07D23902
Patent
active
051853418
ABSTRACT:
The substituted 5-(phenoxyalkanoylamino)-uracil compounds have the following formula I: ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen; a branched or linear alkyl group having 1 to 6 carbon atoms; a branched or straight chain alkenyl or alkynyl group having 1 to 6 carbons atoms; a cycloalkyl group having from 3 to 7 carbon atoms or a cycloalkylmethyl group having a cycloalkyl residue of 3 to 7 carbon atoms; or a phenylalkyl group having an alkyl residue having from 1 to 3 carbon atoms and a phenyl residue, the phenyl residue being unsubstituted or having a halogen, methoxy, methyl or trifluoromethyl substituent; R.sub.3 is a hydrogen, methyl or amino groups; R.sub.4 is halogen, methoxy or methyl groups, and n is 1 or 2. Pharmaceutical compositions for treating cerebrovascular, neuronal-degenerative and senility-induced disorders associated with learning, memory and cognitive dysfunctions are described which contain a therapeutically effective amount of the substituted 5-(phenoxyalkanoylamino)-uracil in a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4746352 (1988-05-01), Wenper et al.
patent: 4908368 (1990-03-01), Murase et al.
patent: 4912109 (1990-03-01), Bapley et al.
March, Advanced Org. Chem. 3rd Edition pp. 370-371, Reaction 0-54.
Susan J. Sara et al., Psychopharmacologia (Berl) 36, 59-66 (1974).
Hoffmann et al., Pharmazie 38 (1983) p. 869.
Von W. Raake et al., Arzheim-Forsch./Drug Res. 27(7), No. 1, 1977, p. 132.
Ordzhonikidze Antibiotic 24(1979) pp. 659-663.
Arzneim.-Forsch./Drug Res. 36 (11), 1568-1571 (1986).
C. Giurgea "Central Hypoxia Models and Correlations . . . ".
W. Hoffmann, et al. "Influence of AWD 23-15, A New Nootropic . . . ".
W. Hoffmann, et al. "Der Einfluss von Nootropica auf das . . . ".
R. Cumin, et al., Psychopharmacology (1982) 78: 104-111.
A. Rostock, et al., Meth and Find Exp. Clin. Pharmacol. 1989; 11(9).
W. Hoffmann, et al. Pharmazie 43 (1988), H. 4.
H. Kuribara, Japan J. Pharmacol. 48, 494 (988).
Biomed. Biochem. Acta 48 (1989) 2/3, pp. 247-250.
Bartsch Reni
Faust Gottfried
Jansch Hans-Joachim
Lohmann Dieter
Rostock Angelika
Arzneimittelwerk Dresden GmbH
Striker Michael J.
Tsang Cecilia
LandOfFree
Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods f does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods f, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods f will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-325750